Dupilumab Reduces Asthma Disease Burden and Recurrent SCS Use in Patients with CRSwNP and Coexisting Asthma

Figures & data

Table 1 Baseline Demographics and SCS Use During the Treatment Period

	Placebo (n = 170)	Dupilumab 300 mg q2w (n = 167)
History of asthma exacerbation, n (%)^a	127 (74.7)	116 (69.5)
SCS use in previous 2 years, n (%)	130 (76.5)	122 (73.1)
Blood eosinophils, 10^9/L, mean (SD)	0.51 (0.38)	0.54 (0.43)
Baseline FEV1, L, mean (SD)
With history of asthma exacerbation^a	2.57 (0.85)	2.61 (1.07)
Without history of asthma exacerbation^a	2.77 (0.76)	2.64 (0.75)
With prior SCS use	2.64 (0.85)	2.70 (1.01)
Without prior SCS use	2.54 (0.77)	2.41 (0.88)
Baseline percent predicted FEV1, %, mean (SD)
With history of asthma exacerbation^a	83.60 (18.60)	84.67 (22.07)
Without history of asthma exacerbation^a	87.76 (15.79)	80.99 (18.13)
With prior SCS use	84.25 (16.35)	84.96 (21.89)
Without prior SCS use	85.86 (22.69)	79.69 (17.84)
Baseline ACQ-6 score (0–6), mean (SD)
With history of asthma exacerbation^a	1.69 (1.14)	1.55 (1.10)
Without history of asthma exacerbation^a	1.58 (0.93)	1.36 (0.92)
With prior SCS use	1.66 (1.05)	1.48 (1.07)
Without prior SCS use	1.65 (1.22)	1.53 (1.01)
SCS use during the treatment period, n (%)	68 (40.0)	20 (12.0)
Reason for SCS use, n (%)^b
NP	45 (66.2)	5 (25.0)
Asthma	16 (23.5)	4 (20.0)
Other respiratory disease	9 (13.2)	4 (20.0)
Other ear, nose, or throat disease	8 (11.8)	2 (10.0)
Other reason	6 (8.8)	11 (55.0)
Number of SCS courses, n (%)^b
1	41 (60.3)	11 (55.0)
2	11 (16.2)	6 (30.0)
3	7 (10.3)	2 (10.0)
≥4	9 (13.2)	1 (5.0)
Total SCS duration, days, median (range)	12.0 (1.0–74.0)	6.5 (1.0–263.0)
Prescribed total SCS dose, mg^c
Mean (SD)	505.6 (629.4)	575.3 (1134.8)
Median (range)	367.5 (10.0–4700.0)	181.7 (26.7–4871.5)

Notes: ^aAsthma exacerbation was defined as an exacerbation requiring SCS or hospitalization (>24 hours) for treatment of asthma and was determined using medical records. ^bPercentages calculated using the number of patients with SCS use during the treatment period as the denominator (placebo n = 68 and dupilumab n = 20). ^cPrednisone-equivalent dosage.

Abbreviations: ACQ-6, 6-item Asthma Control Questionnaire; FEV₁, forced expiratory volume in 1 s; NP, nasal polyps; q2w, every 2 weeks; SCS, systemic corticosteroids; SD, standard deviation.

Figure 1 Kaplan–Meier plot of time to first use of SCS during the treatment period in patients with CRSwNP and coexisting asthma (A) overall and (B) by history of asthma exacerbation^a or (C) prior SCS use.

Notes: ^aAsthma exacerbation was defined as an exacerbation requiring SCS or hospitalization (>24 hours) for treatment of asthma and was determined using medical records. All p-values are nominal.

Abbreviations: CI, confidence interval; CRSwNP, chronic rhinosinusitis with nasal polyps; HR, hazard ratio; q2w, every 2 weeks; SCS, systemic corticosteroids.